OMCL
$35.09
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the heal...
Recent News
How The Titan XT Cycle Is Rewriting The Omnicell (OMCL) Investment Story
Omnicell’s updated analyst narrative keeps the modeled fair value steady at US$57.43, even as some price targets are being revised in different directions. On one side, bullish analysts point to the Titan XT cabinet lineup and a potential replacement cycle as reasons to lift targets; more cautious voices are trimming theirs based on timing and execution risks around that same story. As you read on, you will see how these opposing calls shape the evolving case for following Omnicell from...
Will Strong Q4 Beat and Software Pivot Change Omnicell's (OMCL) Investment Narrative?
Omnicell recently reported Q4 2025 results that exceeded its own guidance across revenue, product bookings, and annual recurring revenue, while launching the Titan XT system to extend intelligent medication management into nursing care areas. Alongside this, the company is accelerating a shift from hardware-centric sales toward software, services, and acquisitions such as ANiGENT, aiming to build a larger base of recurring, healthcare IT–style revenue. Now we’ll examine how Omnicell’s...
3 Reasons to Avoid OMCL and 1 Stock to Buy Instead
Over the past six months, Omnicell has been a great trade, beating the S&P 500 by 19.8%. Its stock price has climbed to $41.48, representing a healthy 26.4% increase. This performance may have investors wondering how to approach the situation.
Omnicell, Inc. (OMCL): A Bull Case Theory
We came across a bullish thesis on Omnicell, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on OMCL. Omnicell, Inc.’s share was trading at $38.61 as of February 18th. OMCL’s trailing P/E was 912.50 according to Yahoo Finance. Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. OMCL is positioning itself […]
3 Cash-Producing Stocks We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.